Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Payal Kohli

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|November 26, 2011
Statins and safety: can we finally be reassured?Payal Kohli, Christopher P Cannon
Journal of the American College of Cardiology|August 18, 2012
Danger ahead: watch out for indirect comparisons!Christopher P Cannon, Payal Kohli
Evidence-Based Medicine|June 29, 2012
Dabigatran associated with increased risk of acute coronary eventsPayal Kohli, Christopher Paul Cannon
The Canadian Journal of Cardiology|July 1, 2014
Looking for coronary disease in patients with atrial fibrillationPayal Kohli, David D Waters
European Heart Journal|April 18, 2012
A new approach to managing the 'statin-intolerant' patient?Payal Kohli, Christopher P Cannon
Journal of Cardiovascular Pharmacology and Therapeutics|April 13, 2013
Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapiesPayal Kohli, Robert P Giugliano
Nature Reviews. Cardiology|December 21, 2011
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleedingPayal Kohli, Christopher P Cannon
Clinical Cardiology|November 30, 2012
The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes dataPayal Kohli, Christopher P Cannon
Circulation|May 6, 2020
Surfing the Waves of the COVID-19 Pandemic as a Cardiovascular ClinicianPayal Kohli, Salim S Virani
British Journal of Pharmacology|July 15, 2009
Resolvins and protectins: mediating solutions to inflammationPayal Kohli, Bruce D Levy
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|November 26, 2011
Statins and safety: can we finally be reassured?Payal Kohli, Christopher P Cannon
Journal of the American College of Cardiology|August 18, 2012
Danger ahead: watch out for indirect comparisons!Christopher P Cannon, Payal Kohli
Evidence-Based Medicine|June 29, 2012
Dabigatran associated with increased risk of acute coronary eventsPayal Kohli, Christopher Paul Cannon
The Canadian Journal of Cardiology|July 1, 2014
Looking for coronary disease in patients with atrial fibrillationPayal Kohli, David D Waters
European Heart Journal|April 18, 2012
A new approach to managing the 'statin-intolerant' patient?Payal Kohli, Christopher P Cannon
Journal of Cardiovascular Pharmacology and Therapeutics|April 13, 2013
Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapiesPayal Kohli, Robert P Giugliano
Nature Reviews. Cardiology|December 21, 2011
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleedingPayal Kohli, Christopher P Cannon
Clinical Cardiology|November 30, 2012
The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes dataPayal Kohli, Christopher P Cannon
Circulation|May 6, 2020
Surfing the Waves of the COVID-19 Pandemic as a Cardiovascular ClinicianPayal Kohli, Salim S Virani
British Journal of Pharmacology|July 15, 2009
Resolvins and protectins: mediating solutions to inflammationPayal Kohli, Bruce D Levy
Pageof 5